SEC Filings

Arcus Biosciences Puts Quarter-End Cash At About $694.0 Million, Unaudited

The preliminary figure covers cash and securities as of September 30 and has not been reviewed by the company's outside auditor.

Arcus Biosciences estimates it held approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026, according to an 8-K filed Wednesday. The number is preliminary and unaudited, and the filing says it is not a full picture of the company's results.

What the 8-K says

The Hayward, California company made the estimate under Item 2.02 of the form, which covers results of operations and financial condition. It is based on information available to management as of October 21, 2026.

The company said the balance is subject to completion of its financial closing procedures, including management's reviews. It warned the figure "may vary from its actual financial position as of September 30, 2026."

The filing adds that the company may identify items that require adjustments to the number. It also says the estimate is not a comprehensive statement of its financial results or financial condition at quarter-end.

What it changes

Nothing in the filing replaces the full quarterly report. The company said the estimate is no substitute for financial statements prepared under U.S. generally accepted accounting principles, and that more information would be needed to understand its financial position fully.

Ernst & Young LLP, the company's independent auditor, has not audited, reviewed, examined or compiled the data, and has not applied agreed-upon procedures to it. The firm "does not express an opinion or any other form of assurance" on it. The figure is the responsibility of management.

The filing also says the estimate is not necessarily indicative of the balance in any future period. The information is furnished rather than "filed" for purposes of Section 18 of the Securities Exchange Act.

Arcus shares closed at $19.10 on Wednesday, down 19.58% from $23.75 at the prior session's close. The filing was accepted by EDGAR at 4:09 p.m. ET, and the filing gives no link between the share move and the estimate.

The 8-K was signed by Chief Executive Officer Terry Rosen, Ph.D.; the audited full-quarter picture is still to come.